Masimo (MASI) Issues FY19 Earnings Guidance

Share on StockTwits

Masimo (NASDAQ:MASI) issued an update on its FY19 earnings guidance on Wednesday morning. The company provided EPS guidance of $3.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.04. The company issued revenue guidance of $910 million, compared to the consensus revenue estimate of $906.53 million.

NASDAQ:MASI opened at $113.16 on Friday. Masimo has a 52 week low of $80.69 and a 52 week high of $126.89. The company has a market capitalization of $5.94 billion, a P/E ratio of 46.19, a PEG ratio of 2.36 and a beta of 0.99.

Masimo (NASDAQ:MASI) last announced its earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.02. The firm had revenue of $210.58 million during the quarter, compared to analysts’ expectations of $207.62 million. Masimo had a return on equity of 20.29% and a net margin of 17.08%. The company’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.56 earnings per share. Analysts expect that Masimo will post 2.92 EPS for the current fiscal year.

MASI has been the subject of a number of recent analyst reports. BidaskClub cut Masimo from a buy rating to a hold rating in a research report on Tuesday, November 13th. Stifel Nicolaus upped their target price on Masimo from $112.00 to $145.00 and gave the stock a buy rating in a research report on Tuesday, October 2nd. Zacks Investment Research cut Masimo from a hold rating to a sell rating in a research report on Thursday, January 3rd. Piper Jaffray Companies increased their price objective on Masimo to $120.00 and gave the company a neutral rating in a research report on Thursday, November 1st. Finally, UBS Group started coverage on Masimo in a research report on Tuesday, November 27th. They issued a buy rating and a $137.00 price objective for the company. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $119.00.

In other news, COO Anand Sampath sold 30,000 shares of the stock in a transaction that occurred on Wednesday, November 28th. The stock was sold at an average price of $110.00, for a total value of $3,300,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Sanford Fitch sold 2,000 shares of the stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $110.90, for a total value of $221,800.00. The disclosure for this sale can be found here. Insiders sold 34,000 shares of company stock valued at $3,748,080 over the last three months. 12.60% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This story was first posted by Macon Daily and is the property of of Macon Daily. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

See Also: What Factors Can Affect Return on Equity?

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with's FREE daily email newsletter.

Leave a Reply